{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T13:01:54Z","timestamp":1780923714482,"version":"3.54.1"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100012141","name":"University Hospitals Bristol and Weston NHS Foundation Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012141","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000866","name":"Cardiff University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000866","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine and Research"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.resmer.2025.101218","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T11:19:20Z","timestamp":1761650360000},"page":"101218","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Skin side-effects of elexacaftor-tezacaftor-ivacaftor: a real-world view"],"prefix":"10.1016","volume":"89","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4066-6432","authenticated-orcid":false,"given":"Sophie","family":"Constantinou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Webber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Darby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devika","family":"Sunil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirain","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Goodwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Duckers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.resmer.2025.101218_bib0001","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/apa.15155","article-title":"Cystic fibrosis in the year 2020: a disease with a new face","volume":"109","author":"De Boeck","year":"2020","journal-title":"Acta Paediatr"},{"issue":"3","key":"10.1016\/j.resmer.2025.101218_bib0002","article-title":"Elexacaftor-tezacaftor-ivacaftor: a life-changing triple combination of CFTR modulator drugs for cystic fibrosis","volume":"16","author":"Bacalhau","year":"2023","journal-title":"Pharm (Basel)"},{"issue":"2","key":"10.1016\/j.resmer.2025.101218_bib0003","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.pharmthera.2009.10.006","article-title":"Cystic fibrosis: exploiting its genetic basis in the hunt for new therapies","volume":"125","author":"Kreindler","year":"2010","journal-title":"Pharmacol Ther"},{"issue":"19","key":"10.1016\/j.resmer.2025.101218_bib0004","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resmer.2025.101218_bib0005","first-page":"383","article-title":"Cystic fibrosis: what next for the \u201cwonder drug\u201d Kaftrio?","author":"Wise","year":"2023","journal-title":"BMJ"},{"key":"10.1016\/j.resmer.2025.101218_bib0006","unstructured":"Summary of product characteristics | European Medicines Agency [Internet]. [cited 2024 Jul 29]. Available from: https:\/\/www.ema.europa.eu\/en\/glossary\/summary-product-characteristics"},{"issue":"1","key":"10.1016\/j.resmer.2025.101218_bib0007","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1001\/jamadermatol.2022.5208","article-title":"Acneiform eruption following elexacaftor-tezacaftor-ivacaftor treatment in patients with cystic fibrosis","volume":"159","author":"Okroglic","year":"2023","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.resmer.2025.101218_bib0008","unstructured":"Dealing with acne caused by trikafta [Internet]. [cited 2024 Jul 23]. Available from: https:\/\/cystic-fibrosis.com\/living\/trikafta-acne"},{"issue":"6","key":"10.1016\/j.resmer.2025.101218_bib0009","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.jcf.2022.09.002","article-title":"Drug-induced acne with elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis","volume":"21","author":"Hudson","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.resmer.2025.101218_bib0010","doi-asserted-by":"crossref","DOI":"10.3390\/children10030554","article-title":"Efficacy and safety of elexacaftor-tezacaftor-ivacaftor in the treatment of cystic fibrosis: a systematic review","volume":"10","author":"Kapouni","year":"2023","journal-title":"Children"},{"key":"10.1016\/j.resmer.2025.101218_bib0011","unstructured":"British association of dermatologists [Internet]. [cited 2025 Mar 29]. Available from: https:\/\/www.bad.org.uk\/pils\/acne\/"},{"key":"10.1016\/j.resmer.2025.101218_bib0012","unstructured":"Overview | Acne vulgaris: management | Guidance | NICE [Internet]. [cited 2024 Jul 24]. Available from: https:\/\/www.nice.org.uk\/guidance\/ng198"},{"key":"10.1016\/j.resmer.2025.101218_bib0013","article-title":"Acne vulgaris","volume":"1-3","author":"Sutaria","year":"2023","journal-title":"Encycl Pharm Pr Clin Pharm"},{"issue":"5","key":"10.1016\/j.resmer.2025.101218_bib0014","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.jcf.2024.04.007","article-title":"Concentrations of dehydroepiandrosterone-sulphate (DHEA-S) in people with cystic fibrosis on and off elexacaftor-tezacaftor-ivacaftor","volume":"23","author":"Abid","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.resmer.2025.101218_bib0015","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jcf.2021.11.012","article-title":"Effect of elexacaf tor-tezacaf tor-ivacaf tor on body weight and metabolic parameters in adults with cystic fibrosis","volume":"21","author":"Petersen","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.resmer.2025.101218_bib0016","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.jcf.2023.06.010","article-title":"Body mass index and nutritional intake following Elexacaftor\/Tezacaftor\/Ivacaftor modulator therapy in adults with cystic fibrosis","volume":"22","author":"Caley","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.resmer.2025.101218_bib0017","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.clindermatol.2016.10.007","article-title":"Drug-induced acne","volume":"35","author":"Kazandjieva","year":"2017","journal-title":"Clin Dermatol"},{"issue":"4","key":"10.1016\/j.resmer.2025.101218_bib0018","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1046\/j.1440-0960.1999.00363.x","article-title":"Night blindness precipitated by isotretinoin in the setting of hypovitaminosis A","volume":"40","author":"Welsh","year":"1999","journal-title":"Australas J Dermatol"},{"issue":"5","key":"10.1016\/j.resmer.2025.101218_bib0019","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/j.1540-9740.2006.04514.x","article-title":"Rietschel RL. Improvement of cystic fibrosis during treatment with isotretinoin","volume":"5","author":"Buckley","year":"2006","journal-title":"Skinmed"},{"issue":"8","key":"10.1016\/j.resmer.2025.101218_bib0020","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1136\/adc.2008.156406","article-title":"Treatment of acne with oral isotretinoin in patients with cystic fibrosis","volume":"94","author":"Perera","year":"2009","journal-title":"Arch Dis Child"},{"issue":"3","key":"10.1016\/j.resmer.2025.101218_bib0021","doi-asserted-by":"crossref","DOI":"10.5070\/D3223030371","article-title":"Isotretinoin therapy for the treatment of acne in patients with cystic fibrosis: a case series and review of the literature","volume":"22","author":"Bari","year":"2016","journal-title":"Dermatol Online J"},{"issue":"4","key":"10.1016\/j.resmer.2025.101218_bib0022","first-page":"004","article-title":"Severe abdominal pain and acne vulgaris after the initiation of elexacaftor \/tezacaftor\/ivacaftor (ELX\/TEZ\/IVA)","volume":"12","author":"Yousseff","year":"2021","journal-title":"IJCMCR"},{"issue":"3","key":"10.1016\/j.resmer.2025.101218_bib0023","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s40257-025-00924-0","article-title":"Morbilliform eruptions: differentiating low-risk drug eruptions, severe cutaneous adverse reactions, viral eruptions, and acute graft-versus-host disease","volume":"26","author":"Yan","year":"2025","journal-title":"Am J Clin Dermatol"},{"issue":"8","key":"10.1016\/j.resmer.2025.101218_bib0024","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1111\/bcp.15490","article-title":"Drugs and the skin: a concise review of cutaneous adverse drug reactions","volume":"90","author":"Del Pozzo-Maga\u00f1a","year":"2024","journal-title":"Br J Clin Pharmacol"}],"container-title":["Respiratory Medicine and Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590041225000650?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590041225000650?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T12:11:56Z","timestamp":1780920716000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590041225000650"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":24,"alternative-id":["S2590041225000650"],"URL":"https:\/\/doi.org\/10.1016\/j.resmer.2025.101218","relation":{},"ISSN":["2590-0412"],"issn-type":[{"value":"2590-0412","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Skin side-effects of elexacaftor-tezacaftor-ivacaftor: a real-world view","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine and Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.resmer.2025.101218","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 SPLF and Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101218"}}